Alkem Laboratories Limited (NSE: ALKEM)
India
· Delayed Price · Currency is INR | Market Cap | 646.40B |
| Revenue (ttm) | 128.32B |
| Net Income (ttm) | 21.22B |
| Shares Out | 119.57M |
| EPS (ttm) | 177.51 |
| PE Ratio | 30.46 |
| Forward PE | 27.29 |
| Dividend | 40.00 (0.73%) |
| Ex-Dividend Date | Aug 9, 2024 |
| Volume | 28,643 |
| Open | 5,481.90 |
| Previous Close | 5,481.90 |
| Day's Range | 5,383.55 - 5,488.15 |
| 52-Week Range | 4,407.05 - 6,439.90 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 7, 2025 |
About Alkem Laboratories
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also p... [Read more]
Financial Performance
In 2023, Alkem Laboratories's revenue was 126.68 billion, an increase of 9.21% compared to the previous year's 115.99 billion. Earnings were 17.96 billion, an increase of 82.47%.
Financial StatementsNews
Alkem Laboratories to transfer trade generics business to Alkem Wellness for Rs 750 crore
Alkem Laboratories has recently informed exchanges that the company will transfer its trade generics business to its subsidiary, Alkem Wellness Ltd., for up to ₹750 crore. In FY24, this business gener...
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
BofA flags structural risks in domestic pharma; maintains ‘Underperform’ on Mankind and Alkem, ‘Neutral’ on Torrent Pharma
Bank of America (BofA) has raised concerns about structural challenges in the domestic pharmaceutical sector, citing margin risks from slowing volume growth and unaccounted regulatory pricing pressure...
Jefferies maintains underperform on Alkem Labs with target at ₹4,950, indicating 11.1% downside
Jefferies has maintained its Underperform rating on Alkem Laboratories with a target price of ₹4,950, suggesting an 11.1% downside from the current market price (CMP) of ₹5,565.15. The company’s Q2 re...
Nomura on Alkem Labs: Maintains Neutral call, raises target, expects 9.6% upside to Rs 6,097
Nomura has maintained a Neutral rating on Alkem Labs, with a revised target price of ₹6,097 per share, reflecting a 9.6% increase from the current market price (CMP) of ₹5,565.15. The company anticipa...
Alkem Laboratories Q2 FY25 Results: Revenue up 0.7% YoY to ₹3,414.67, Net Profit up 14.2% YoY
Alkem Laboratories Q2 FY25 Financial Results Highlights: Revenue from Operations: Quarter-over-Quarter (QoQ): Revenue rose to ₹3,414.67 crore in Q2 FY25 from ₹3,031.82 crore in Q1 FY25. Year-over-Year...
Brigade Enterprises shares dip nearly 4% ahead of Q2 FY25 earnings
Shares of Brigade Enterprises Ltd were trading 3.90% lower at ₹1,080.90 on the NSE as of 11:44 a.m. on November 13, 2024, ahead of the company’s Q2 FY25 results. Brigade is among several companies exp...
Adani Energy shares surge over 5% today – Know why
Shares of Adani Energy Solutions rose by 5% as it joins five other Indian stocks expected to enter the MSCI Standard Index in its upcoming rebalancing on November 6. The final announcement, set for We...
Alkem signs licensing agreement with Sonnet to combat diabetic neuropathy with new drug development
Alkem Laboratories Limited has announced a significant partnership with US-based Sonnet BioTherapeutics Holdings, Inc. to develop, manufacture, and commercialize the drug candidate “SON-080” for the t...
Alkem labs denies its products, Pan-D and Clavam 625, failed quality test
Alkem Laboratories has denied allegations by the CDSCO that certain batches of its products, Pan-D and Clavam 625, failed to meet quality standards. The company asserted that the samples in question w...
Alkem Laboratories denies claims of its Pan-D and Clavam 625 products being not of standard quality
Alkem Laboratories has recently denied claims that batches of its Pan-D and Clavam 625 products are not of standard quality. The company conducted an investigation and found that the CDSCO samples wer...
Novartis India stock surges 9% as Alkem Labs eyes ₹2,000 crore acquisition
Novartis India (BSE: ₹1,181.70) surged 8.95% in intraday trading at 3:02 PM, following reports by CNBC-TV18 indicating that Alkem Labs is in talks to acquire the company from its Swiss parent, Novarti...
JB Chemicals faces valuation dispute over KKR’s 54% equity stake, potential M&A deal withdrawal looms; stock falls 4.28%
The largest M&A deal in India’s pharmaceutical industry for 2024 is reportedly facing significant hurdles. According to ET Now, JB Chemicals is in a disagreement over the valuation of KKR’s 54% equity...
Jefferies on Alkem Labs: ‘Underperform’ with a Target of ₹5,080
Jefferies has issued an “Underperform” rating on Alkem Laboratories, setting a target price of ₹5,080 per share. According to the management, boosting operational margins is the company’s top priority...
Alkem Laboratories sees ₹487 crore block deal as promoter likely offloads stake
On August 22, Alkem Laboratories witnessed a significant block deal, with shares worth ₹487 crore changing hands. It is likely that the company’s promoters were the sellers in this transaction. Key De...
Alkem Laboratories Ltd (BOM:539523) Q1 2025 Earnings Call Transcript Highlights: Strong EBITDA ...
Alkem Laboratories Ltd (BOM:539523) Q1 2025 Earnings Call Transcript Highlights: Strong EBITDA Margin and Regulatory Compliance
Q1 2025 Alkem Laboratories Ltd Earnings Call Transcript
Q1 2025 Alkem Laboratories Ltd Earnings Call Transcript